Regenicin, Inc. Announces Repayment of Loans From Financial Backers
17 Junio 2011 - 8:00AM
Marketwired
Regenicin, Inc. (OTCBB: RGIN), a biotechnology company specializing
in the development of regenerative cell therapies to restore the
health of damaged tissues and organs, recently repaid short-term
secured loans totaling $242,993.54.
Regenicin, Inc. received these short-term loans from supporters
of the company, including members of its board of directors, to
finance operations. The repayment fully satisfied the terms of the
loans, and released the company's assets that were held as security
for the loans.
The three board members who were reimbursed for their loan
contributions were Dr. Craig Eagle, John Weber and Dr. Joseph
Rubinfeld.
"The short-term loans extended to us were from people who
genuinely want us to succeed in bringing new product candidates to
market in the field of regenerative medicine," says Randall McCoy,
CEO of Regenicin. "We are pleased to have the financial wherewithal
to repay these valuable contributors and continue on our path to
fulfill our business objectives."
About Regenicin Regenicin, Inc. (OTCBB:
RGIN), is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged
tissues and organs.
Regenicin, which was founded in 2010, has assembled a
world-class management team with a proven track record for
developing and bringing innovative medical devices and
biotechnology products to market. The company is publicly traded
with headquarters in New Jersey.
Safe Harbor Statement. This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are based on
the current plans and expectations of management and are subject to
a number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Allison Van Ness 646-403-3581 Email Contact
Regenicin (CE) (USOTC:RGIN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Regenicin (CE) (USOTC:RGIN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024